home / stock / tota / tota quote
Last: | $10.82 |
---|---|
Change Percent: | -12.46% |
Open: | $11.88 |
Close: | $10.82 |
High: | $11.95 |
Low: | $10.7 |
Volume: | 354,205 |
Last Trade Date Time: | 12/30/2020 04:56:30 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.82 | $11.88 | $10.82 | $11.95 | $10.7 | 354,205 | 12-30-2020 |
$12.36 | $14.3 | $12.36 | $15 | $11.35 | 379,863 | 12-29-2020 |
$12.97 | $12.61 | $12.97 | $17.5 | $11.9 | 688,373 | 12-28-2020 |
$11.45 | $11.1 | $11.45 | $12.08 | $10.8517 | 53,037 | 12-25-2020 |
$11.45 | $11.1 | $11.45 | $12.08 | $10.8517 | 53,037 | 12-24-2020 |
$11.01 | $11.1 | $11.01 | $11.23 | $10.9827 | 60,333 | 12-23-2020 |
$10.97 | $11.1 | $10.97 | $11.25 | $10.9655 | 488,433 | 12-22-2020 |
$10.96 | $10.9495 | $10.96 | $11 | $10.55 | 79,268 | 12-21-2020 |
$11.105 | $10.5 | $11.105 | $11.105 | $10.5 | 4,138 | 12-18-2020 |
$11.21 | $11.25 | $11.21 | $11.25 | $10.97 | 148,968 | 12-17-2020 |
$11.04 | $11.14 | $11.04 | $11.14 | $11.02 | 2,343 | 12-16-2020 |
$11.1 | $11.0286 | $11.1 | $11.1 | $11.02 | 4,916 | 12-15-2020 |
$11.0199 | $11.2 | $11.0199 | $11.2 | $10.94 | 23,400 | 12-14-2020 |
$11.11 | $11.1 | $11.11 | $11.5 | $11.0877 | 5,562 | 12-11-2020 |
$11.0007 | $11.4431 | $11.0007 | $11.4431 | $11.0007 | 3,333 | 12-10-2020 |
$11.1624 | $11.12 | $11.1624 | $11.25 | $10.9 | 4,429 | 12-09-2020 |
$11.11 | $11.47 | $11.11 | $11.47 | $11.0028 | 8,105 | 12-08-2020 |
$11.245 | $11.3 | $11.245 | $11.3 | $11.245 | 8,239 | 12-07-2020 |
$11.24 | $11.25 | $11.24 | $11.25 | $11.2115 | 2,497 | 12-04-2020 |
$11.207 | $11.2 | $11.207 | $11.207 | $11.2 | 637 | 12-03-2020 |
News, Short Squeeze, Breakout and More Instantly...
Tottenham Acquisition I Limited Company Name:
TOTA Stock Symbol:
NASDAQ Market:
NEW YORK , Sept. 10, 2020 /PRNewswire/ -- Tottenham Acquisition I Limited (Nasdaq: TOTA, TOTAU, TOTAW, TOTAR) ("Tottenham"), a publicly traded special purpose acquisition company, announced today that its subsidiary, Chelsea Worldwide Inc., has filed with the U.S. Securities and Exchang...
Clene is a clinical-stage biopharmaceutical company developing the first potential therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the n...